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The androgen receptor (AR) is a ligand-activated transcription
factor required for male sex development and virilization and con-
tributes to prostate cancer initiation and progression. High affinity
androgen binding triggers conformational changes required for AR
transactivation. Herewe characterized naturally occurringAR gene
mutations in the region of activation function 2 (AF2) that decrease
or increase AR transcriptional activity by altering the region
bounded by AF2 and the ligand binding pocket without affecting
equilibrium androgen binding affinity. In the androgen insensitiv-
ity syndrome, germ line ARmutations increase the androgen disso-
ciation rate and reduce AR FXXLF motif binding and the recruit-
ment of steroid receptor coactivator (SRC)/p160 coactivator LXXLL
motifs. In prostate cancer, somatic ARmutations inAF2 or near the
bound ligand slow androgen dissociation and increase AR stabiliza-
tion and coactivator recruitment. Crystal structures of the AR
ligand binding domain bound to R1881 and FXXLF or LXXLLmotif
peptide indicate the mutations are proximal to the AF2 bound pep-
tide, adjacent to the ligand pocket, or in a putative ligand gateway.
The results suggest a bidirectional structural relay between bound
ligand and coactivator that establishes AR functional potency in
vivo.
Steroid receptors comprise a subgroup of the nuclear receptor family
of transcriptional activators that regulate gene expression by recruiting
coactivator proteins (1). Like other steroid receptors, the androgen
receptor (AR)3 mediates transcriptional activation primarily through
two domains. Activation function 1 (AF1) in theNH2-terminal region is
the major transactivation domain (2) but is not well conserved across
species (3). Activation function 2 (AF2) in the ligand binding domain is
a highly conserved hydrophobic surface that is stabilized by agonist
binding and required for SRC/p160 coactivator recruitment. AF2 is
formed by helices 3, 3, 4, and 12 and is flanked by clusters of oppositely
charged residues (4). AR binding of the biologically active androgens
testosterone and dihydrotestosterone (DHT) is thought to stabilize the
AF2 helix 12 to complete the coactivator binding surface (5–7).
The humanAR gene is expressed at chromosomeXq11-12 as a single
allele in the 46,XY genetic male. More than 300 different AR single
amino acid mutations or partial gene deletions cause the androgen
insensitivity syndrome (AIS). Partial loss of AR function results in male
infertility and varying degrees of incompletemasculinization. Complete
loss of AR function results in an external female genital phenotype in the
genetic male (8, 9). Mutations in the AR gene occur in the human pop-
ulation with a frequency of 0.002%, with single base changes over-
whelmingly positioned in the highly structured ligand binding domain.
Mutations in theAF2 region of the ligand binding domain can causeAIS
without altering equilibrium androgen binding affinity (10, 11).
For the steroid receptors as a group, AF2 serves as a critical if not
essential binding site for the LXXLL motifs of SRC/p160 coactivators
that have histone acetyltransferase activity (12). However, AR is unique
because AF2 displays different affinities for multiple LXXLL-related
motifs. Like other steroid receptors in the presence of agonist, AR AF2
binds the LXXLL motifs of SRC/p160 coactivators but with an affinity
5–10 times weaker than that of the AR NH2-terminal FXXLF motif
sequence 23FQNLF27 (10, 13, 14). AR FXXLF motif binding to AF2
mediates the androgen-dependent NH2- and carboxyl-terminal (N/C)
interaction that has been shown to be important for androgen-regulated
gene expression (11, 15). AR has in addition an NH2-terminal WXXLF-
binding motif (433WHTLF437) that contributes to the N/C interaction
by binding AF2 (14, 16, 17). AR transactivation through AF2 in the
presence of agonist appears to be limited not only by the lower binding
affinity for the coactivator LXXLL motifs but also through competitive
inhibition of coactivator binding by the AR FXXLF motif.
Beneath the exterior surface of the ARAF2 coactivator-binding site is
a shallow interface juxtaposed against the ligand binding pocket. This
close structural arrangement provides a platform for potential commu-
nication between AF2 and bound ligand in regulating AR transcrip-
tional activity. Support for structural communication at this boundary
region is evident from the slower androgen dissociation that results
from FXXLF motif binding to AF2 (11, 15, 18). Coactivator LXXLL
motif binding may similarly induce conformational changes in AF2 and
impact ligand binding kinetics (13, 16). Here we investigated structural
features and functional consequences of the naturally occurring AR
germ line and somatic mutations in or near the AF2 site in search of
evidence for a structural relay between AF2 and the ligand binding
pocket. In the AR-linked disorders of androgen insensitivity and pros-
tate cancer, AR genemutations have opposite effects onAR activity that
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involve the N/C interaction, androgen dissociation rates, and coactiva-
tor recruitment.
EXPERIMENTAL PROCEDURES
Plasmids—pCMVhAR vectors expressing full-length human AR
with the followingmutations were described: I737T and F725L (10, 19);
V889M (20); E897K and I898T (10); K720A (4, 10); H874Y (21); and
T877A (22). Other vectors used were as follows: VP-AR-(1–660) (11,
14); transcriptional intermediary factor 2 (TIF2)-AR fusion protein
TIF2(LXXLL)3AR-(172–919) (18); pSG5-TIF2 and VP-TIF2-(624–
1287) (VP-TIF2.1) (23); wild-type and mutant pcDNA3-AR-(624–919)
(10, 14); and 5XGAL4Luc3 (16). GST-SRC1-IV (GST-SRC1-(1139–
1441)) was created by digesting GAL-SRC1-(1139–1441) with XbaI
(blunt-ended) and BamHI, and the fragment was subcloned into
pGEX-3X digestedwith EcoRI (blunt-ended) and BamHI. GST-AR-(4–
52) (GST-AR-FXXLF) was created by PCR amplifying pACT2-AR-(4–
52), digesting the fragment with EcoRI and XhoI, and subcloning into
pGEX-4T-1 digested with the same enzymes. AIS and prostate cancer
mutations were introduced into GAL-AR-(624–919) by PCR amplifi-
cation of the corresponding mutant pCMVhAR and cloning the XbaI
and NdeI fragments into GAL-AR-(624–919) digested with the same
enzymes. pCMVhAR-(507–919) vectors (2) containing the indicated
mutations were created by digesting full-length mutant pCMVhAR
with KpnI and BamHI and cloning the fragment into pCMV5 digested
with the same enzymes. pCMVhAR vectors containing AIS mutations
G743V, Q733A, L712F, and V715M were created using a double PCR
strategy. TIF2(LXXLL)3AR-(172–919)-AXXAA containing the V715M
or H874Y mutation was constructed by digesting the corresponding
pCMVhAR mutant with HindIII and XbaI. The fragments were sub-
cloned into similarly digested TIF2(LXXLL)3AR-(172–919)-AXXAA.
TIF2(LXXLL)3AR-(172–919)-AXXAA-T877Awas created by digesting
GAL-AR-(624–919)-T877A with Csp45I and XbaI and inserting the
fragment into TIF2(LXXLL)3AR-(172–919)-AXXAA digested with
the same enzymes. TIF2(LXXAA)3AR-(172–919) vectors containing
V715M, H874Y, and T877A were created by digesting the correspond-
ing pCMVhAR mutant with Csp45I and XbaI and inserting the frag-
ment into similarly digested TIF2(LXXAA)3AR-(172–919). All PCR
amplified regions were verified by DNA sequencing.
Crystal Structure Analysis—Coordinates of the wild-type AR ligand
binding domain boundwith R1881 and either AR-(20–30)-FXXLF pep-
tide RGAFQNLFQSV, TIF2 LXXLL peptide KENALLRYLLDKDD, or
no peptide, Protein Data Bank (www.rcsb.org) access codes 1XOW,
2AO6, and 1XQ3, respectively (13), were examined with regard to the
functional data from AR mutations in AIS and prostate cancer. The
structures were viewed with QUANTA (Accelrys, Inc.) and rendered
and annotated with PyMol version 0.98 (Delano Scientific, www.
pymol.org) and Adobe Photoshop.
Cell Transfections—Transcriptional activities of wild-type and
mutant full-length human AR (pCMVhAR) were determined in tran-
sient cotransfection assays. Monkey kidney CV1 cells were maintained
in Dulbecco’s modified Eagle’s medium containing 10% bovine calf
serum, 2 mM L-glutamine, 20 mM Hepes, pH 7.2, penicillin, and strep-
tomycin. CV1 cells (4.2  105/6 cm dish) were plated in the same
medium except containing 5% bovine calf serum, and the next day the
cells were transfected with 0.1 g of wild-type or mutant pCMVhAR
and 5 g of the PSA-Enh-Luc reporter (Michael Carey, University of
California Los Angeles) (4). For the effects of SRC/p160 coactivators,
pSG5-TRAM1 (2 g DNA/6 cm dish) was included. After incubating
with the calcium phosphate-DNA precipitate for 4 h at 37 °C, cells were
shocked with 15% glycerol-containing medium, washed, and trans-
ferred to serum-free medium lacking phenol red in the absence and
presence of the indicated steroids. Cells were incubated overnight and
the next day placed in serum-free medium with and without the indi-
cated hormones. The medium was exchanged and incubated for an
additional 24 h at 37 °C with or without hormone. Cells were washed
with phosphate-buffered saline and harvested in 0.5 ml of lysis buffer
containing 25 mM Tris phosphate, pH 7.8, 2 mM EDTA, 1% Triton
X-100. After 30min rocking at room temperature, 100-l aliquots were
analyzed for luciferase activity using an automated LumiStar Galaxy
(BMG Labtech) multiwell plate reader luminometer.
Two-hybrid interaction assays were performed using human epithe-
lioid cervical carcinoma HeLa cells. HeLa cells were maintained in
Eagle’s minimum essential medium (Invitrogen) supplemented with
10% fetal bovine serum (Sigma), 2mML-glutamine, penicillin, and strep-
tomycin.HeLa cells were plated in 12-well plates (5 104 cells/well) and
transfected using Effectene (Qiagen) or FuGENE (Roche Applied Sci-
ence) with 50 ng/well GAL-AR-(624–919), 50 ng/well VP-AR-(1–660),
and 0.1 g of 5XGAL4Luc3 reporter vector. For the Effectene proce-
dure, the DNA transfection mixture contained 50 l of transfection
buffer (Qiagen), 1 l of Enhancer, and 1 l of Effectene per well (4). To
each DNAmixture was added 0.4ml of serum-containingmedium, and
0.4ml was added to each well containing 0.8ml of fresh serum-contain-
ingmedium. For the FuGENE transfection, 43l of serum-freemedium
and 0.6 l of FuGENE were combined per well, and after a 15-min
incubationwith theDNA, 40l of themixturewas added perwell. After
24 h, cells were washed, and serum-free medium (2 ml) lacking phenol
red was added with and without the indicated steroids. Cells were incu-
bated overnight, and 100 l of the cell lysate was assayed for luciferase
activity after harvesting in 0.25 ml of lysis buffer as described above.
Transcription assays of AR activity were performed in HeLa cells as
described above using per well of 12-well plates the following: 10 ng of
wild-type or mutant pCMVhAR, 0.25 g of PSA-Enh-Luc, in the
absence and presence of 50 ng/well pSG5-TIF2.
In Vitro Binding Assays—Competitive binding and ligand dissocia-
tion studies were performed at 37 °C in whole cell binding assays by
plating 4  105 COS cells/well of 6-well plates and transfecting 1 g of
wild-type or mutant pCMVhAR or pCMVhAR-(507–919) per well
using DEAE-dextran (4). Cells were incubated for 2 h at 37 °C in
0.6 ml of serum-free medium lacking phenol red and containing
5 nM [3H]R1881 (17-methyl-[3H]methyltrienolone; 82 Ci/mmol),
[1,2,4,5,6,7-3H]dihydrotestosterone (DHT, 124 Ci/mmol), or [1,2,6,7-
3H]testosterone (78.5 Ci/mmol) (PerkinElmer Life Sciences). Nonspecific
bindingwas determined by the addition of a 100-foldmolar excess of unla-
beledandrogen.Forcompetitivebindingstudies, increasingconcentrations
of unlabeled ligands were added during the 2-h incubation. For ligand dis-
sociation studies, unlabeled androgen was added to the labeling media in
0.1ml ofmedium to a final concentration of 50M, and ligand dissociation
at 37 °C was terminated at increasing time intervals up to 2.5 h. Cells were
washed with phosphate-buffered saline, and total bound radioactivity was
determined by lysing cells in 0.5 ml of 2% SDS, 10% glycerol, and 20 mM
Tris, pH6.8.Dissociationhalf-timesweredetermined as themeanS.E. of
the time required to reduce specific androgen binding activity by 50%.
Equilibrium binding constants were determined by transfecting 2 
105 COS cells/well of 12-well plates with 0.05 g of wild-type and
mutant pCMVhAR expression vector DNA using DEAE-dextran. Cells
were incubated with 0.1, 0.2, 0.4, 0.8, 1.5, and 3 nM [3H]R1881 in the
absence and presence of a 100-fold molar excess of unlabeled R1881 to
assess nonspecific binding. Free [3H]R1881 was determined after the
2-h incubation by counting an aliquot of the medium. Cells were
washed and harvested, and radioactivity was determined. In the in vitro
Androgen Receptor Mutations at the AF2-Ligand Boundary
MARCH 10, 2006 • VOLUME 281 • NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 6649
affinity matrix binding assays, GST fusion proteins were expressed, iso-
lated, and incubated with [35S]methionine-labeled AR ligand binding
domain residues 624–919 as described (10, 14).
Degradation Assays—Wild-type and V715M, H874Y, or T877A
pCMVhAR (10 g/10-cm dish) was expressed in COS cells (2  106/
10-cm dish) plated in Dulbecco’s modified Eagle’s medium containing
10% bovine calf serum (Hyclone) and transfected using DEAE-dextran.
After 24 h, transfected cells were placed in serum-free medium. 48 h
from transfection, cells were incubated for 20min at 37 °C in serum-free
medium lacking phenol red and methionine. To the NEG-772 Easytag
Express protein labeling mixture, L-[35S]methionine (1175 Ci/mmol;
PerkinElmer Life Sciences) was added at 80 Ci/dish, and cells were
incubated for 20 min at 37 °C. The medium was changed to serum-free
without phenol red and containing 2 mM cold methionine and 1 nM
testosterone, and cells were incubated for the indicated times. At each
time point the medium was replaced on all plates. At the indicated
times, cells were washed and harvested in phosphate-buffered saline
and lysed in freshly prepared RIPA buffer (1 ml/dish) containing 1%
TritonX-100, 1% deoxycholate, 0.1% SDS, 0.15 MNaCl, 5mMEDTA, 50
mMTris-HCl, pH 7.4, proteinase inhibitor mixture (Roche Applied Sci-
ence), 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride
(Sigma). Cell extracts were incubated with 25 g of AR52 IgG antibody
and 10 l of protein A-agarose beads (Sigma) for 2 h at 4 °C. Affinity
beads were centrifuged and washed with RIPA buffer, and protein was
eluted in 50 l of sample buffer containing 4% SDS, 20% glycerol, 0.2%
2-mercaptoethanol, and 20mMTris-HCl, pH 6.8, and separated on 10%
acrylamide gels containing SDS. The gel proteins were transferred to
nitrocellulose membranes and exposed to x-ray film. Degradation half-
timeswere determined from semi-logarithmic plots of optical density of
the scanned AR bands versus time and are expressed as the mean half-
time and standard error to reduce AR levels by 50% from three inde-
pendent experiments.
FIGURE 1. Scatchard plots of [3H]R1881 binding to wild-type AR and AR AIS and prostate cancer mutants. Equilibrium androgen binding affinities were determined at 37 °C in
cultured COS cells transiently expressing wild-type (WT) and mutant AR as described under “Experimental Procedures.” A and B, representative data are shown for full-length WT AR
and AR AIS mutants I737T, F712L, I898T, Q733H, V889M, and G743V. C, representative data are shown for full-length WT AR and AR prostate cancer mutants H874Y, T877A, and V715M.
Apparent equilibrium androgen binding affinities (see Table 1) were determined from the means of at least three independent experiments. B/F, bound/free.
TABLE 1
[3H]R1881 dissociation and affinity constants from AR AF2 mutants
Helix position in the ligand binding domain is indicated for AR AIS and charge clamp mutations. AIS grade is based on a 1–7 scale where grade 1 is mild AIS, and grades
6 and 7 are complete AIS (9). Half-times (t1⁄2 in min) of [3H]R1881 dissociation were determined at 37 °C in COS cells for full-length wild-type and mutant AR-(1–919) and
ARDNAand ligand binding domain fragmentAR-(507–919). Equilibriumbinding affinities (Kd, nM) for full-lengthwild-type andmutantARwere determined by Scatchard




AR-(507–919), Diss t1⁄2 min Codon change Ref.Diss t1⁄2 min Kd
nM
AR-WT 107  5 0.40  0.20 33  9
F725L 3/4 loop 3–5 86  5 0.82  0.32 31  2 TTC3CTC 10, 19
I737T 4 1–3 81  3 0.44  0.20 38  0 ATT3ACT 10, 19
G743V 5 4–5 58  6 0.16  0.06 19  3 GGG3GTG 76–78
Q733H 4 3–4 34  3 0.30  0.30 30  4 CAG3CAT 79, 80
L712F 3 3 26  3 0.42  0.17 20  1 CTT3GTT 81
I898T 12 6 21  2 0.34  0.02 6  2 ATT3ACT 10, 80
V889M 11/12 loop 6 9  1 0.46  0.25 4  2 GTG3ATG 82–86
K720A 3 101  14 0.54  0.15 27  4
E897K 12 38  4 0.52  0.18 34  5
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RESULTS
Rapid Dissociation of Bound Androgen Correlates with Reduced AR
Activity in Vivo—The relationship between androgen dissociation rate
and AR functional activity was investigated by characterizing naturally
occurring ligand binding domain germ linemutations in AF2 and flank-
ing regions that cause partial or complete AIS. AR mutations L712F,
F725L, Q733H, I737T, G743V, V889M, and I898T result from single
base changes in the coding sequence. Equilibrium binding affinities (Kd)
for [3H]R1881 (a synthetic androgen) were similar to that of wild-type
AR (Table 1). Representative Scatchard plot analysis of the AR AIS
mutants is shown in Fig. 1, A and B. On an AIS grading scale of 1–7 (9),
the 46,XY genetic males had phenotypes that ranged from the mildest
grade 1 with normal male external genitalia and gynecomastia (I737T),
moderate grades 3–5 with ambiguous genitalia (F725L, I737T, G743V,
Q733H, and L712F), and complete AIS grade 6 with external female
phenotype (I898T and V889M) (9).
The dissociation half-time (t1⁄2) of [3H]R1881 for full-length wild-type
AR expressed in COS cells at 37 °C was 107 min (Table 1). More rapid
androgen dissociation was observed for AR with mutations F725L and
I737T (t1⁄2  81–86min), G743V,Q733H, and L712F (t1⁄2  26–58min),
and I898T and V889M (t1⁄2  9–21 min) (Fig. 2A). Mean half-times of
[3H]R1881 dissociation (Table 1) suggest that faster androgen dissocia-
tion correlates with a more severe AIS phenotype. By comparison, AF2
charge clamp mutation K720A did not alter androgen dissociation,
whereas E897K caused more rapid androgen dissociation. Neither
charge clamp mutation has been reported in AIS.
Androgen dissociation rates were also measured for AR-(507–919),
an AR DNA and ligand binding domain fragment that lacks the NH2-
terminal region. Androgen dissociation from AR-(507–919) (t1⁄2  33
min) is3 times faster than from full-lengthAR (Table 1), reflecting the
absence of the N/C interaction (14). Apparent equilibrium binding
affinity of AR-(507–919) for [3H]R1881 is nevertheless similar to that of
wild-type full-length AR (20). Naturally occurring mutations can there-
fore alter androgen dissociation kinetics through differentmechanisms.
Mutations inAF2 can directly interferewith FXXLFmotif binding in the
N/C interaction, alter a ligand entry and exit gateway, or have indi-
rect effects through structural changes in AF2 and the ligand binding
pocket. Studies using AR-(507–919) allowed us to distinguish these
possibilities.
Androgen dissociation fromAR-(507–919) containing F725L, I737T,
or Q733H (t1⁄2  30–38 min) was similar to that of wild-type AR-(507–
919) (Fig. 2B and Table 1), indicating this subgroup of AR mutations in
AIS does not directly alter ligand entry or exit from the binding pocket.
AR-(507–919) containing G743V or L712F increased androgen disso-
ciation (t1⁄2  19–20min), and I898T andV889M caused themost rapid
rates of androgen dissociation (t1⁄2 4–6min) (Fig. 2B andTable 1) (10).
The results suggest that F725L, I737T, and Q733H located in helices
3–5 alter ligand dissociation indirectly in the ligand binding pocket
through changes at the AF2 surface that interfere with the N/C inter-
action. This subgroup of mutations cause partial AIS with phenotypic
variation (Table 1). The rapid androgen dissociation rate of AR-(507–
919) I898T suggests AF2 residue Ile-898 also impacts the ligand binding
pocket from the AF2 surface. The fast androgen dissociation caused by
V889M in the 11/12 loop at the base of helix 12 outside the ligand
binding pocket suggests Val-889 is involved as gatekeeper for ligand
entry and exit. Both I898T and V889M caused grade 6 complete AIS.
AR AF2 Mutations That Cause AIS Interfere with AR FXXLF and
Coactivator LXXLL Motif Binding—A mammalian two-hybrid assay
revealed that these ARAIS AF2mutations inhibited FXXLF and LXXLL
binding to a similar extent. GAL-AR-(624–919) containing the AR
ligand binding domain was coexpressed with VP-AR-(1–660) contain-
ing AR NH2-terminal FXXLF motif sequence 23FQNLF27 (Fig. 3A) or
VP-TIF2-(624–1287) containing the three LXXLL motif regions of
TIF2 (Fig. 3B). Relative to thewild-typeAR ligand binding domain inter-
action, only 5–30% luciferase activity remained for the AIS mutants in
the presence of 0.1 and 1 nM DHT. Similarly, charge clamp mutation
FIGURE 2. Increased androgen dissociation of AR AIS mutations. Dissociation rates of
[3H]R1881 were measured at 37 °C in cultured COS cells transiently expressing wild-type
(WT) and mutant AR and AR-(507–919) as described under “Experimental Procedures.” A,
representative data are shown as indicated for full-length WT AR (AR-(1–919)) and AR AIS
mutants I737T, G743V, F725L, Q733H, L712F, I898T, and V889M. B, representative data
are shown as indicated for AR-(507–919), a DNA and ligand binding domain fragment,
with WT sequence and AR-(507–919) mutants I737T, F725L, Q733H, L712F, G743V, I898T,
and V889M. Dissociation half-times (see Table 1) were calculated from three independ-
ent experiments and are the mean times required for 50% reduction in binding activity.
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E897K disrupted both FXXLF and LXXLL motif binding, whereas
K720A selectively inhibited LXXLL motif binding.
Structure Analysis and Predictions for ARMutations in AIS—Cocrys-
tal structures of the R1881-AR ligand binding domain complex bound
to the FXXLF or LXXLLmotif peptide demonstrated similar yet distinc-
tive properties (13). The sites of 5 of the 7 residues mutated in AIS lie in
close proximity to the bound FXXLF peptide (magenta in Fig. 4 and 5) or
LXXLL peptide (not shown). Interatomic distances between wild-type
residues mutated in AIS (cyan in Figs. 4 and 5) and the bound FXXLF or
LXXLL peptide motifs are summarized in Table 2.
Our structural analysis began with mutations near the Phe-23 i  1
residueofFXXLF that cause a spectrumofAISphenotypes (Table1),where
i  1 to i  5 designate residues of the FXXLF and LXXLL motifs. AF2
residues Leu-712 (helix 3, H3), Ile-737 (H4), and Ile-898 (H12) form a close
hydrophobic cluster (designatedAIS group 1) proximal to i 1 nearest the
ligand binding pocket (Figs. 4 and 5A). AIS group 1 mutations weakened
motif binding and caused faster androgen dissociation kinetics, both of
which interferewithAR activity in vivo as evidenced by theAIS phenotype.
L712F in helix 3 increased androgen dissociation from full-lengthAR,
with a half-time similar to that of AR-(507–919) with the same muta-
tion. This suggests the principal effect of L712F is to disrupt favorable
FXXLF motif binding to AF2, with secondary effects in the ligand bind-
ing region. Leu-712 is 4.1 Å from Phe-23 and 3.6 Å from a prominent
helix 5 residue Trp-7414 situated above and close to the B-, C-, and
D-rings of R1881 (Fig. 5A). Leu-712 is surrounded by hydrophobic res-
idues i  4 Leu-26, Val-716 (H3), Ile-737 (H4), and Met-894 (H12).
Introduction of the large phenylalanine side chain by L712F potentially
disrupts FXXLF motif binding by directly altering favorable hydropho-
bic packing and contacts to Phe-23 and Leu-26, thereby weakening the
protection of bound ligand afforded by the N/C interaction. L712F may
also influenceMet-894, a residue adjacent to helix 12 residuesMet-895,
Glu-897, and Ile-898, and reduce a stabilizing effect of helix 12 on the
bound ligand. Unfavorable interactions between L712F and Trp-741
independent of the N/C interaction may account for the moderately
faster ligand dissociation from AR-(507–919) L712F.
In contrast, I898T in helix 12 caused complete AIS and rapid andro-
gen dissociation from full-length AR andAR-(507–919). Ile-898 is 4.4 Å
from Phe-23 of the bound peptide, 5.3 Å from Trp-741, and is sur-
rounded by Leu-712 (H3), Gln-738 (H4), Met-895 (H12), and Gln-902
(H12). I898T introduces a polar side chain near residue Gln-738, a side
4 From our original report (13), a recent report (75), and as shown here, the absence of a
C-19 methyl group in R1881 allows the Trp-741 and Met-745 side chains to adopt a
conformation that differs from previously reported AR structures bound with DHT
that has the C-19 methyl (34, 38). In more recent refinements not detailed here, we
found our R1881 crystallographic data to be most consistent with the Trp-741 side
chain conformed in roughly equal occupancy with one rotamer very similar to that
shown here with R1881 and the other similar to that seen with DHT. This further
supports the ligand-dependent dynamic properties of Trp-741 in the ligand binding
pocket.
FIGURE 3. Effect of AIS and charge clamp mutations on AR FXXLF and TIF2 LXXLL
motif binding to AF2 in the AR ligand binding domain. In two-hybrid interaction
assays, HeLa cells (50,000 cells/well of 12-well plates) were transfected using Effectene or
FuGENE with 0.1 g/well 5XGAL4Luc reporter vector. A, VP-AR-(1– 660) (50 ng/well) con-
taining the VP16 transactivation domain and AR NH2-terminal and DNA binding domain
residues 1– 660 was transfected with the indicated GAL-AR-(624 –919) mutants (50
ng/well) containing the AR ligand binding domain with wild-type sequence or the indi-
cated mutation. B, VP-TIF2-(624 –1287) (50 ng/well) containing the VP16 transactivation
domain and the TIF2-(624 –1287) three LXXLL motif region was transfected with the
indicated GAL-AR-(624 –919) mutants (50 ng/well). Transfected cells were incubated for
24 h in the absence and presence of 0.1 and 1 nM DHT. Shown is the mean percent activity
and error of the GAL-AR-(624 –929) mutants compared with the activity of wild-type
GAL-AR-(624 –929) from at least four independent measurements.
FIGURE 4. Wild-type AF2 and ligand binding pocket region of the AR ligand binding
domain bound with R1881 and AR-(20 –30) FXXLF peptide (Protein Data Bank
access code 1XOW). Ribbon rendering is used to represent the ligand binding domain
(translucent yellow backbone) and AR FXXLF peptide 20RGAFQNLFQSV30 (translucent
magenta backbone with opaque magenta side chains for Phe-23, Leu-26, and Phe-27).
Wild-type AR side chains altered in AIS (cyan) and prostate cancer (orange) are illustrated
along with charge clamp residues Glu-897 (translucent red backbone, yellow side chain,
and red oxygen) and Lys-720 (translucent blue backbone, yellow side chain, and blue
nitrogen), ligand binding pocket residues Asn-705, Trp-741, Met-745, Arg-752 (gray side
chains, blue nitrogen, red oxygen, and orange sulfur), and R1881 (green carbon and red
oxygen).
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chain in wild-type AR that rearranges to stack against Phe-23 upon
binding the FXXLFmotif. I898Tmay contribute to a hydrogen bonding
network involving side chains from Gln-738, Gln-902, and Lys-905
(H12) as evident in the peptide-free structure (13). This contribution
may influence the helix 12 equilibrium to favor an unbound AF2 with
reduced motif binding affinity and thus shorten the lifetime of the
bound ligand. Alternatively, I898Tmay simply disrupt favorable hydro-
phobic contacts in the region by presenting too much polarity in the
region near Phe-23.
In I737T, threonine again replaces isoleucine. However, I737T is less
disruptive than I898T based on androgen dissociation kinetics and the
AIS phenotype. Unlike Ile-898 and Leu-712, Ile-737 is centered between
i  1 and i  5 (3.7 Å from Phe-23 and 3.9 Å from Phe-27) and more
distant (6.4 Å) from Trp-741 in the ligand binding pocket compared
with Leu-712 (3.6 Å) and Ile-898 (4.2 Å) (Table 2 and Fig. 5, A and B).
I737T in helix 4 introduces a polar side chain into a richly hydrophobic
region comprised of Leu-712, Val-715, Val-716, Ala-719, Phe-725, Val-
736, Leu-812, Ile-898, and the i  1 Phe-23 and i  5 Phe-27 residues.
The near wild-type ligand dissociation half-time for AR-(507–919)
I737T but the faster dissociation half-time for full-length AR I737T
comparedwithwild-typeAR suggests that I737T interferes with FXXLF
motif binding at the i 1 and i 5 sites by disrupting local hydrophobic
interactions with adjacent AF2 residues rather than greatly disturbing
residues in the ligand binding domain interior.
A second AF2 hydrophobic center (designated AIS group 2) is com-
prised of residues Phe-725 (H3), Gln-733 (H4), and Ile-737 (H4) from
AIS group 1. These residues reside within 4.6 Å of i  5 of either bound
peptide near the Lys-720 charge clamp (Figs. 4 and 5B), andGln-733 and
Phe-725 are more remote to the ligand-binding site than is Ile-737. AIS
group 2 mutations account for reduced motif binding and shorter
androgen dissociation half-time, both of which interfere with AR activ-
ity in vivo evidenced by the AIS phenotype. AR F725L and I737T mod-
estly shortened the R1881 dissociation half-time compared with
Q733H. The greater effect of Q733Hmay arise from a change in the 3 Å
hydrogen bond contributed by Gln-733 N-2 to the Leu-728 backbone
carbonyl, aswell as the introduction of the polar aromatic imidazole side
chain near i  5 Phe-27 and Phe-725 (Fig. 5B). F725L preserves the
hydrophobic character of the region, even though a large planar phenyl
ring is replaced by the smaller branched leucine side chain that would
alter the shape complementarity and regional hydrophobic contacts
between Phe-725 and the i  5 site. Given their close proximity to i  5
and remote location to the ligand binding pocket and near wild-type
ligand dissociation rate of AR-(507–919), AIS mutations F725L and
Q733Hmost likely decrease androgen retention times by directly inter-
fering with FXXLF motif binding in the i  5 region.
The remaining two AIS mutations, G743V and V889M, respectively,
cause moderately severe and complete AIS in correlation with the
ligand dissociation kinetics in Table 1. Gly-743 in helix 5 located just
FIGURE 5. Close up views of wild-type AR AF2
and ligand binding pocket bound with R1881
and AR-(20 –30) FXXLF peptide (color scheme
from Fig. 4). A, wild-type residue side chains for
group 1 AIS mutations L712F, I737T, and I898T
near i  1 Phe-23 of the 23FQNLF27 motif. Leu-712
and Ile-898 are proximal to Trp-741, whereas the
more distal Ile-737 lies between Phe-23 and
Phe-27 as seen in B. Intermolecular distances (Å,
dashed black lines) are indicated between Trp-741
to Ile-898, Leu-712, Met-895, and Ile-899. B, wild-
type residue side chains for group 2 AIS mutations
F725L, Q733H, and I737T near the i  5 Phe-27 of
the 23FQNLF27 motif. Phe-725 and Gln-733 are
located near the Lys-720 and the carboxyl-termi-
nal end of the FXXLF motif, whereas Ile-737 is cen-
tered between Phe-23 and Phe-27. C, wild-type
residue side chains for AIS mutants G743V and
V889M. Gly-743 resides in helix 5 close to Trp-741
in the ligand binding pocket core. Val-889 in the
helix 11–12 linker may serve a gatekeeper function
in a possible ligand gateway near helices 3, 6, 11,
and 12.
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outside AF2 in the hydrophobic core near Trp-741, Met-745, and the
ligand binding pocket (Fig. 5C) faces Val-866 in helix 10 and is sur-
rounded by Met-742 (H5), Val-746 (H5), Leu-811 (H8), Val-866 (H10),
Gln-867 (H10), and Ala-870 (H10). The 2-fold more rapid androgen
dissociation half-time caused by G743V in full-length AR suggests
destabilizationof the ligandbindingpocket and interferencewith ligand-
dependent FXXLFmotif binding. Replacing a flexible glycinewith valine
may render helix 5 too rigid to allow neighboring core residues to adjust
and contact the ligand optimally or it may simply destabilize the helix 5
coil and/or key packing interactions near helices 10 and 11.
Ligand trafficking through an opening assembled by the NH2 termi-
nus of helix 3, helix 11, the 11–12 linker, andAF2 helix 12was supported
by the effects of V889M, a mutation that caused complete AIS. Val-889
lies in the linker region preceding theAF2 helix 12 distant fromAF2 and
the bound peptidemotif (Fig. 4 and Fig. 5C and Table 2). Val-889 is near
the ligand binding pocket, 6 Å from D-ring substituents of the bound
ligand and 3.5 Å from Asn-705, a residue that hydrogen bonds with the
ligand C-17 hydroxyl group and is adjacent to Phe-876 (H10), Phe-891,
Leu-880 (H11), Leu-701 (H3), and Phe-697 (H3). Methionine residues
are notable for their flexible and accommodating side chain. However,
in this case it appears that the longer side chain and large sulfur atom of
V889M disturbs the largely hydrophobic region and destabilizes the
linker region and equilibrium position of the AF2 helix 12. A key inter-
action between Asn-705 and the steroid D-ring may also be disrupted
and reduce the lifetime of the bound ligand without significantly alter-
ing the equilibrium binding constant.
AR Mutations in Prostate Cancer Slow Androgen Dissociation—Sev-
eral somatic mutations in prostate cancer occur in the AR AF2 and
ligand binding region (24). These include V715M (25), H874Y (21, 26),
T877A (22, 27), V730M (25, 28), and R726L (29). These prostate cancer
mutations result from single base changes and do not significantly alter
the apparent equilibrium binding affinity of [3H]R1881 (Fig. 1C and
Table 3). Valines 715 and 730 are in the hydrophobic core of AF2;
Arg-726 is in the positive charge cluster flanking AF2 (4), and His-874
and Thr-877 are in helix 10 adjacent to AF2 helix 12. Neither V730M
nor R726L change the androgen dissociation rate, and no difference
from wild-type AR was observed for AR R726L in two-hybrid assays of
motif binding (data not shown). R726L was identified as a germ line
mutation in the Finnish population (29, 30) and lacks a strict clinical
correlation with prostate cancer. V730M selectively increases SRC1
LXXLL motif binding (13).
Remarkably, three ARmutations in prostate cancer, V715M, H874Y,
and T877A, slowed the dissociation rate of bound androgen relative to
wild-type AR (Fig. 6A). The half-times of [3H]R1881 dissociation
increased 2-fold from t1⁄2  107 min for wild-type AR to t1⁄2  207–212
min for AR V715M, H874Y, and T877A (Table 3). Longer dissociation
half-times of [3H]DHT and [3H]testosterone were also observed. Tes-
tosterone dissociation from AR H874Y was 4.5-fold slower than from
wild-type AR. Normally testosterone dissociates 3 times faster than
DHT from full-length wild-type AR (Table 3) and is a weaker androgen
in vivo (31).
The effects of the mutations were also evident in the absence of the
N/C interaction because they slowed the dissociation of R1881 from
AR-(507–919) (Fig. 6B). Dissociation half-times of [3H]R1881 from
AR-(507–919) containing V715M,H874Y, or T877Awere2-fold lon-
ger (t1⁄2  60–82 min) compared with the wild-type fragment (t1⁄2  31
min) (Table 3). Other AR ligand binding domain mutations reported in
prostate cancer retained high affinity equilibrium binding (8) but did
not slow dissociation of [3H]R1881. These included G750S (t1⁄2  123
min), S782N (t1⁄2  93 min), A896T (t1⁄2  88 min), and L701H (t1⁄2  28
min). Thus a slower androgen dissociation depends largely on the posi-
tion of the mutation in the ligand binding domain.
TABLE 2
Interatomic distances (in Å) between bound AR FXXLF peptide, TIF2
LXXLL peptide, and AR Trp-741 to AR ligand binding domain
residues
Interatomic distances (Å) are from the AR FXXLF peptide, the TIF2 third LXXLL
peptide, or AR Trp-741 to the indicated ligand binding domain atoms. The first
residue of the FXXLFor LXXLLmotif is i 1.Atomdesignations adhere to standard
IUPAC nomenclature.
TABLE 3
[3H]Androgen dissociation and affinity constants for AR prostate cancer mutants
Helix position in the ligand binding domain is indicated for the sites of AR prostate cancer mutations. Half-times (t1⁄2 in min) of [3H]R1881, [3H]DHT, and [3H]testosterone
(T) dissociation (Diss) were determined at 37 °C in COS cells for wild-type andmutant full-length AR (amino acid residues 1–919). [3H]R1881 dissociation was determined
for wild-type and mutant AR-(507–919). Equilibrium binding affinities (Kd, nM) of [3H]R1881 for wild-type and mutant full-length AR were determined by Scatchard plot
analysis. Binding constants are the mean  S.E. from three independent assays. Nucleotide base changes are indicated for AR mutations in prostate cancer.
AR Helix
Full-length AR
AR-(507–919), Diss t1⁄2 min, R1881 Codon changeDiss t1⁄2 min Kd,
R1881R1881 DHT T
nM
Wild-type 107  5 206  30 59  3 0.40  0.20 31  3
V715M 3 207  43 298  78 101  5 0.79  0.25 70  8 GTG3ATG
H874Y 10 212  53 324  60 266  15 0.56  0.37 60  7 CAT3TAT
T877A 10 208  37 240  48 143  15 0.75  0.30 82  12 ACT3GCT
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Increased AR Transcriptional Activity and Coactivator Recruitment—
The effects of the prostate cancermutations on AR transcriptional activity
were determined in the absence and presence of SRC/p160 coactivator
coexpression.With transient coexpression of p160 coactivatorTRAM-1 in
CV1 cells, AR V715M, H874Y, and T877A increased transcriptional
activity relative to wild-type AR in response to 0.01 nM testosterone
(Fig. 7A). Transcriptional activity was also greater with the more
potent androgen DHT; however, the effects of the mutations were
less evident in the presence of DHT. In the absence of transient
coactivator expression or at higher levels of androgen, no major
differences in AR transcriptional activity were observed in CV1 cells
(data not shown). However, in HeLa cells that express higher endog-
enous levels of SRC/p160 coactivators (32), prostate cancer muta-
tions V715M, H874Y, and T877A increased AR activity in the pres-
ence of testosterone (Fig. 7B). For AR V715M, transcriptional activity
also increased with coexpression of TIF2. Increases in transcriptional
activities of the three mutants over wild-type AR were noted in both
cell lines in the presence of 1 nM 4-androstene-3,17-dione (data not
shown).
The increase in AR transcriptional activity and slower dissociation of
bound androgen by two of the mutants was associated with increased
binding of the FXXLF or LXXLL motifs to the AR carboxyl-terminal
region in GAL-AR-(624–919). In two-hybrid assays, V715M and
H874Y increased FXXLF (Fig. 8A) and LXXLL (Fig. 9A) motif binding
over that of the wild-type AR in the presence of DHT or testosterone.
For the FXXLF motif in VP-AR-(1–660), greater increases in binding
indicative of the ARN/C interaction were observed using 0.1 nM testos-
terone or DHT. For the LXXLL motif in VP-TIF2-(624–1287),
increases in transcriptional activity were apparent in response to low
levels of androgen. Increased FXXLF and LXXLL motif binding by the
mutants relative to wild-type AR was also observed in response to the
adrenal androgens, 4-androstene-3,17-dione and 5-androstane-
3,17-diol (Figs. 8B and 9B). However, no increase in motif binding
was detected with ART877A in the presence of these androgens (Figs. 8
and 9).
Competitive ligand binding assays confirmed that V715M, H874Y,
and T877A did not alter AR binding affinity for R1881, DHT, testoster-
one, 4-androstene-3,17-dione, or 5-androstane-3,17-diol (Fig. 10).
However, as reported previously (21, 27), LNCaP cell line mutant AR
T877A increased binding of hydroxyflutamide, estradiol, and progester-
one (data not shown).
FIGURE 7. Increased AR transactivation of AR prostate cancer mutants V715M,
H874Y, and T877A. A, CV1 cells (4.2  105/6-cm dish) were transfected using calcium
phosphate DNA precipitation and per dish, 100 ng of pCMVhAR with wild-type or
V715M, H874Y, or T877A mutant sequence, 2 g of pSG5-TRAM1, and 5 g of PSA-Enh-
Luc. Transfected cells were incubated for 40 h in the absence and presence of 0.01 nM
DHT or testosterone (T). B, HeLa cells (5  104/well of 12-well plates) were transfected
using FuGENE by adding per well, 10 ng of pCMVhAR with wild-type or V715M, H874Y, or
T877A mutant sequence, 0.25 g of PSA-Enh-Luc, in the absence or presence of 50 ng of
pSG5-TIF2. Transfected cells were incubated in the absence and presence of 0.1 and 1 nM
testosterone (T), and luciferase activity was determined. Luciferase activities are repre-
sentative of three independent experiments.
FIGURE 6. Slower androgen dissociation of
three AR prostate cancer mutants. Dissociation
rates of [3H]R1881 were measured at 37 °C in cul-
tured COS cells transiently expressing wild-type
(WT) and mutant AR and AR-(507–919) as
described under “Experimental Procedures.” A,
representative data are shown as indicated for full-
length WT AR (AR-(1–919)) and AR AIS mutants
H874Y, T877A, and V715M. B, representative data
are shown as indicated for AR-(507–919) with WT
sequence and AR-(507–919) mutants V715M,
T877A, and H874Y. Dissociation half-times (see
Table 3) were calculated from at least three inde-
pendent experiments and are the mean times
required for 50% reduction in binding activity.
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AR transcriptional activity can therefore increase as a result of AR
mutations in prostate cancer through mechanisms that include
increased FXXLF and LXXLL motif binding and slower dissociation
rates of bound androgen. The absence of a prominent increase in
FXXLF or LXXLLmotif binding by T877A suggests it was the structural
effects imposed by V715M and H874Y rather than the slow androgen
dissociation rate per se that stabilized motif binding.
TIF2 LXXLL-AR Chimeras—Previously, we showed that the ARN/C
interaction between the AR NH2-terminal FXXLF motif and AF2 slows
the dissociation of bound androgen. However, slower androgen disso-
ciation does not occur in the presence of the LXXLLmotif whenARwas
coexpressed with TIF2 (14) or in LXXLL-AR chimeras (18). Because the
V715M and H874Y mutations increased AR FXXLF and TIF2 LXXLL
motif binding to the AR carboxyl-terminal fragment, we determined
whether LXXLL motif binding influences androgen dissociation of
these mutants. Dissociation half-times of [3H]R1881 were determined
for TIF2-AR chimeras in which the AR NH2-terminal region (residues
1–171) containing the FXXLF motif was replaced by the LXXLL motif
region of TIF2 (residues 627–780), and the V715M, H874Y, or T877A
mutation was introduced into the ligand binding domain (Table 4). For
some of the chimeras, LXXAA replaced the TIF2 LXXLL motifs to
establish LXXLLmotif dependence. In others, AXXAA replaced the AR
WXXLFmotif at residues 433–437, amotif that contributes onlyweakly
to the dissociation rate of bound androgen (18).
TIF2-AR chimeras with LXXLL or LXXAA TIF2 sequence had faster
dissociation half-times (t1⁄2  40–48min) comparedwith full-lengthAR
(t1⁄2  107 min) (Table 4). This reflects the absence of the AR N/C
interaction and a weaker interaction of LXXLLmotifs to ARAF2. Intro-
ducing each of the prostate cancer mutations, V715M, H874Y, and
T877A, slowed androgen dissociation, but this was independent of
LXXLL motif binding. A notable exception was V715M, which
increased binding of LXXAA, suggesting this mutation alters motif
binding specificity.
Slow dissociation of androgen from the AR prostate cancer mutants
therefore appears to result from inherent changes in the ligand binding
domain rather than from increased coactivator LXXLL motif binding.
The mutations influence the AF2 boundary with the ligand binding
pocket to stabilize ligand and for two of the mutants, LXXLL motif
binding.
IncreasedMotif Binding in Vitro—GST affinity matrix binding assays
were used to examine further the effect of the AR prostate cancermuta-
tions on LXXLL and FXXLF motif binding. In this assay, the fourth
LXXLLmotif of SRC1 was selected because of its relatively strong bind-
ing to the AR ligand binding domain compared with other LXXLL
motifs (33). 35S-Labeled AR ligand binding domain fragments
AR-(624–919) with wild-type or V715M, H874Y, and T877A mutant
sequences were incubated with GST-SRC1-IV (SRC1 residues 1139–
1441) or GST-AR-FXXLF (AR residues 4–52) (Fig. 11). In the presence
of DHT or testosterone, prostate cancer mutants AR V715M and
H874Y bound the LXXLL and FXXLFmotifs to a greater extent thanAR
T877A or wild-type AR. The data support the increase in intracellular
LXXLL motif binding shown in Figs. 7–9 and provide further evidence
that prostate cancer mutants V715M and H874Y increase LXXLL and
FXXLF motif binding.
Structure Analysis and Predictions for AR Mutations in Prostate
Cancer—Structure of the AR ligand binding domain complexed with
R1881 and FXXLF or LXXLL peptide was analyzed in light of the AR
prostate cancer mutations. The Val-715 side chain in AF2 helix 3 faces
toward the ligand binding pocket and at its closest distance is 5.2 Å
from Trp-741,4 a hydrophobic residue in helix 5 that lies directly above
and contacts the bound ligand (Fig. 12). A hydrophobic space surround-
ing Val-715 created by residues Leu-712, Trp-718, Ile-737, Trp-741,
Leu-744, and Met-745 appears to readily accommodate the V715M
mutation. Compared with valine, the longer, flexible methionine side
chain may better fill the space and stabilize interactions with Trp-741,
possibly strengthening interactions with the ligand that are further
FIGURE 8. Increase in AR FXXLF motif binding by prostate cancer mutations V715M and H874Y. HeLa cells (5  105/well of 12-well plates) were transfected using FuGENE by
adding per well, 0.1 g of 5XGAL4Luc3, 50 ng of GAL-AR-(624 –929) containing wild-type or V715M, H874Y, and T877A mutant AR ligand binding domain, and 50 ng of VP-AR-(1– 660).
Transfected cells were incubated for 24 h in the absence and presence of 0.1 and 1 nM DHT or testosterone (T) (A), and with 1 and 10 nM 4-androstene-3,17-dione (DIONE) or
5-androstane-3,17-diol (DIOL) (B). Luciferase activity and error are representative of three independent experiments.
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transmitted toward the AF2 floor through Ile-898. Altered structural
changes between Trp-741 and AF2 floor residues may enhance shape
complementarity at the AF2 floor and facilitate FXXLF and LXXLL
motif binding.
Located in helix 10, His-874 is on the opposite side of Trp-741 from
Val-715 and farther from the bound peptides (Table 2) but about equi-
distant (5.5 Å) to Trp-741. Through a conservedwater, His-874 engages
in a solvent-mediated hydrogen bond to the backbone of Trp-741 in
helix 5. The H874Y mutation provides more hydrophobicity with a
longer hydroxylated phenyl ring that may displace the conserved water
and directly hydrogen-bond to a helix 5 backbone atom. Direct hydro-
gen bonding could stabilize helix 5, strengthen interactions between
Trp-741 and the bound ligand, and transmit stabilizing effects to the
AF2 floor that enhance FXXLF and LXXLL motif binding.
Helix 10 residues Thr-877 and His-874 are similar distances from
the AF2-bound peptide (Table 2) and like Val-715 are 5.0 Å from
Trp-741. However, in contrast to Val-715 and His-874, Thr-877 has
direct contact with the D-ring hydroxyl of bound DHT (34) and
R1881 (13) through a 2.9 Å hydrogen bond. In contrast, the slower
androgen dissociation rates caused by T877A are associated with a
hydrophilic to hydrophobic residue change, loss of a hydrogen bond to the
ligand, and no substantial increase in FXXLF or LXXLL motif binding. It
therefore appears that T877A has a different conformational effect onAF2
than that caused by the V715M and H874Ymutations.
The data indicate that all three AR prostate cancer mutations that
slow the dissociation rate of bound androgen are positioned near
(V715M and H874Y) or in (T877A) the ligand binding pocket and may
influence the conformation of Trp-741, a hydrophobic residue that
directly contacts the bound ligand. The data suggest that V715M and
H874Y impact not only the ligand binding pocket to slow androgen
dissociation but also the AF2 binding surface to facilitate LXXLL and
FXXLF motif binding.
FIGURE 9. Increase in TIF2 LXXLL motif binding
by prostate cancer mutations V715M and
H874Y. HeLa cells (5  105/well of 12-well plates)
were transfected using FuGENE by adding per
well, 0.1 g of 5XGAL4Luc3, 50 ng of GAL-AR-
(624 –929) containing wild-type or V715M, H874Y,
and T877A mutant AR ligand binding domain, and
50 ng of VP-TIF2-(624 –1287). Transfected cells
were incubated for 24 h in the absence and pres-
ence of 0.001, 0.01, and 0.1 nM DHT or testosterone
(T) (A), or 0.1, 1, and 10 nM 4-androstene-3,17-di-
one (DIONE) or 5-androstane-3,17-diol (DIOL)
(B). Luciferase activity and error are representative
of three independent experiments.
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FIGURE 11. Increased binding of LXXLL and FXXLF motifs to AR prostate cancer
mutants V715M, H874Y, and T877A in vitro. GST affinity matrix binding assays were
performed using GST-0 empty parent vector (lanes 1– 4), GST-SRC1-IV containing the
fourth carboxyl-terminal LXXLL of SRC1 residues 1139 –1441 (lanes 5– 8), and GST-AR-(4 –
52) (GST-AR-FXXLF) containing the AR FXXLF motif in residues 4 –52 (lanes 9 –12). GST-
purified extracts were incubated with pcDNA3-HA-AR-(624 –919) with wild-type or
V715M, H874Y, and T877A mutant sequence in the presence of 1 M DHT or testosterone
(T). The bands represent 35S-labeled HA-AR-(624 –919) with wild-type or indicated
mutant sequence.
TABLE 4
[3H]R1881 Dissociation of TIF2-AR prostate cancer mutation chimeras
Half-times (t1⁄2 in min) of [3H]R1881 dissociation (Diss) were determined at 37 °C in
COS cells for AR and TIF2-AR chimeras containing TIF2-(627–780) LXXLL motif
region expressed NH2-terminal in fusion proteins with AR-(172–919), with and
without the V715M, H874Y, or T877A mutation. LXXAA replaced the three TIF2
LXXLL motifs, and AQNAA replaced the WQNLF residues 433–437 AR region.
The data are the mean  S.E. from three independent assays.
Diss t1⁄2 min
AR 107  5
TIF2(LXXLL)3AR-(172–919)-AXXAA 48  6
TIF2(LXXAA)3AR-(172–919) 40  5
TIF2(LXXLL)3AR-(172–919)-AXXAA-V715M 77  5
TIF2(LXXAA)3AR-(172–919)-V715M 135  24
TIF2(LXXLL)3AR-(172–919)-AXXAA-H874Y 134  6
TIF2(LXXAA)3AR-(172–919)-H874Y 137  18
TIF2(LXXLL)3AR-(172–919)-AXXAA-T877A 126  16
TIF2(LXXAA)3AR-(172–919)-T877A 119  21
FIGURE 10. Steroid binding specificity of AR V715M, H874Y, and T877A mutants in prostate cancer. Competitive binding studies were performed in COS cells (4 
105/well of 6 well plates) using the DEAE-dextran transfection method as described under “Experimental Procedures” with 2 g/well pCMVhAR containing wild-type or
V715M, H874Y, and T877A mutant sequences. Cells were incubated with 5 nM [3H]R1881 in the absence and presence of increasing concentrations of unlabeled R1881 (A), DHT
(B), testosterone (T) (C), 4-androstene-3,17-dione (D), and 5-androstane-3,17-diol (E). Shown are the average percent competitive binding determinations from three
independent experiments.
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Increased AR Stability—The FXXLFmotif-mediated ARN/C inter-
action slows the dissociation rate of bound androgen and stabilizes
AR (11, 18, 35). This link between androgen dissociation rate and AR
stability is evident with potent androgens such as DHT (20) com-
pared with weaker androgens such as testosterone. AR nevertheless
binds testosterone with an equilibrium affinity similar to DHT, but
testosterone dissociates more rapidly and is a less effective androgen
in vivo (20, 31). We therefore investigated whether slower dissocia-
tion of testosterone from the AR prostate cancer mutants increased
AR stabilization.
AR degradation rates were determined in COS cells at 37 °C by
[35S]methionine pulse-chase labeling in the presence of 1 nM testoster-
one (Fig. 13). The half-time of degradation of wild-type AR (t1⁄2  1.8 
0.3 h) was faster than that of AR V715M (t1⁄2  2.8  0.4 h) and AR
H874Y (t1⁄2  3.2  0.4 h) but similar to AR T877A (t1⁄2  2.0  0.5 h).
The results indicate that even though all three mutations prolonged the
androgen dissociation half-time, only V715M and H874Y increased AR
stability in the presence of testosterone.
DISCUSSION
Naturally OccurringMutations Alter the ARAF2 and Ligand Binding
Interface—We have characterized naturally occurring AR mutations in
the region of the ligand binding pocket and AF2 binding surface for AR
FXXLF and coactivator LXXLL motifs. The mutations increased or
decreased AR functional activity in vivo without causing significant
changes in equilibrium androgen binding affinity. Germ line mutations
in AF2 that cause a phenotypic spectrum of AIS increased the androgen
dissociation rate and decreased AR FXXLF and SRC/p160 coactivator
LXXLL motif binding to AF2. Conversely, three AR somatic mutations
in prostate cancer slowed the dissociation rate of R1881 by 2-fold and
testosterone by up to 4.5-fold. Slower androgen dissociation by the
prostate cancer mutants was associated with increased AR transcrip-
tional activity, and for AR V715M and H874Y with increased FXXLF
and LXXLL motif binding to AF2. The location and effect of AIS muta-
tion V889M on ligand dissociation suggest a hormone gateway at the
base of AF2 helix 12 between helices 3, 6, 10, and 12, where Val-889
serves as gatekeeper. Moreover, the effects of the AIS and prostate can-
cer mutations implicate Trp-741 as a critical residue in a structural
interplay between AF2, bound ligand, and residues neighboring the
ligand.
FXXLF and LXXLL Motif Binding to AF2—The AF2 site in steroid
receptors is a hydrophobic surface in the ligand binding domain
required for hormone-dependent SRC/p160 coactivator LXXLL motif
binding (4, 5). AR AF2 has a higher affinity for the AR NH2-terminal
FXXLFmotif than the coactivator LXXLLmotifs (13). Differences in the
apparent relative AR binding affinities for these helical motifs are attrib-
uted in part to flanking residues that interfere with motif binding
depending on peptide length (4, 36, 37).
Structural studies have shown subtle induced fit differences between the
ARAF2binding surfaceswithboundFXXLFandLXXLLpeptides (13).The
i 1motif side chains contact nearly the same side chains inAF2, as do the
i  5 side chains, even with the 2-Å shift in relative position of the two
bound peptides. It was therefore not unexpected that ARmutations in AIS
and prostate cancer studied here had similar effects on the two motifs, i.e.
AISmutations decreased FXXLF and LXXLL binding, and two of the pros-
tate cancer mutations increased binding of these motifs.
Despite similarities in the AF2 binding surface, it is FXXLF motif
binding that slows androgen dissociation (18). This is evident by the3
times faster androgen dissociation rate of AR-(507–919) comparedwith
full-length AR. AR-(507–919) retains high affinity equilibrium andro-
gen binding but lacks the AR NH2-terminal region and thus lacks an
N/C interaction. Disrupting theARN/C interaction bymutations in the
NH2-terminal FXXLF motif (14) or FXXLF motif binding of melanoma
antigen gene protein MAGE-11 (36) also increases intracellular andro-
gen dissociation.
The inability of coactivator LXXLL motif binding to slow androgen
dissociation from AR was evident in previous studies where TIF2 and
AR were coexpressed (14) and from the TIF2-AR chimera studies
reported here. TIF2-AR chimeras with wild-type AR ligand binding
domain had androgen dissociation rates similar to AR-(507–919) and
2.5 faster than full-length AR. Prostate cancer mutations V715M,
H874Y, and T877A slowed androgen dissociation in the chimeras but
not in an LXXLL motif-dependent manner.
Slower androgen dissociation resulting from FXXLFmotif binding to
AF2 suggests that structural changes are transmitted from AF2 to the
ligand binding pocket. However, induced fit conformational changes
noted for the side chains of AF2 charge clamp residues Glu-897 and
Lys-720, along with Met-734 and Met-894 (13, 38), do not visibly alter
the structure of the ligand binding domain core. Clues that Leu-712 and
Ile-898 serve as a conduit for transmission of FXXLF binding to the
ligand binding pocket exist in the ligand dissociation and structural
data. Both L712F and I898T in full-length AR and AR-(509–919)
increase androgen dissociation. Leu-712 is located 4.0 Å and Ile-898 5.8
Å from the Met-894 sulfur atom in helix 12. The fully engaged charge
FIGURE 12. Close up view of the wild-type AR ligand binding pocket region (color
scheme from Fig. 4). Three prostate cancer mutations, V715M, H874Y, and T877A, sur-
round helix 5 residue Trp-741, which lies above R1881 in the steroid-binding site. The
V715M mutation contributes a seventh methionine to the predominantly hydrophobic
ligand binding pocket. The His-874 side chain engages in a water (red sphere)-mediated
hydrogen bond to the backbone of Tyr-741. Residue Thr-877 and Asn-705 hydrogen-
bond to the C-17 hydroxyl group on the steroid D-ring. Intermolecular distances (Å,
dashed black lines) are indicated. The backbone of nearby AIS mutations are in cyan.
FIGURE 13. Increased stabilization of AR prostate cancer mutants in the presence of
1 nM testosterone. Wild-type AR or AR V715M, H874Y, and T877A in pCMVhAR (10
g/dish) were expressed in COS cells (1.8  106 cells/10-cm dish) using the DEAE-dex-
tran transfection method. Cells were placed in serum-free medium without phenol red-
free 24 h after transfection, and 24 h after incubation, cells were incubated with 80 Ci of
[35S]methionine per plate for 20 min in the presence of 1 nM testosterone. Cells were
transferred to serum-free medium containing 2 mM cold methionine and 1 nM testoster-
one and incubated at 37 °C for 0, 2.5, 5, or 8 h as indicated. Cells were harvested, and AR
was immunoprecipitated. Mean AR degradation half-times were determined as
described under “Experimental Procedures.” The x-ray film was exposed for 3 days and is
representative of three independent experiments.
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clamp residues with higher affinity FXXLFmotif binding may provide a
greater stabilizing influence on helix 12 residues such as Met-894 than
the more weakly bound LXXLL motif that lacks an NH2-terminal
hydrogen bond to charge clamp residue Glu-897 (13, 38). Stabilizing
effects passed from helix 12 to Leu-712 and Ile-898 may propagate to
Trp-741, which lies above the ligand pocket, resulting in slower ligand
dissociation.
In contrast, residues Phe-725, Gln-733, and Ile-737 (group 2)
mutated inAIS are situated near Lys-720 inAF2 and i 5 of FXXLF and
are more remote to the ligand binding pocket. AIS mutations F725L,
Q733H, and I737T increase androgen dissociation from full-length AR
but not from AR-(507–919), in agreement with two-hybrid assays that
the AIS group 2 mutations interfere with FXXLF motif binding. Aside
from the notable rearrangement of Lys-720, no remarkable structural
differences are seen between the i  5 region and the ligand binding
pocket when FXXLF is bound. This result and their more remote loca-
tion from the ligand binding pocket suggest that these residues, partic-
ularly Phe-725 and Gln-733, stabilize AR primarily by maintaining the
bound FXXLF motif, which in turn stabilizes the ligand binding core.
Residue Ile-737 lies closer to Trp-741 and may more directly influence
the ligand binding pocket in response to higher affinity FXXLF motif
binding. FXXLF motif binding also influences the position of the Met-
895 side chain that lies close to the steroid D-ring, providing another
link in the signal conduit between bound peptide and ligand binding
core.
The results from AR and other steroid receptors indicate that motif
binding must be high affinity to prolong the half-time of ligand dissoci-
ation. The AR FXXLFmotif peptide binds AF2 with higher affinity than
the LXXLLmotif peptide (13), and it is FXXLF motif binding that slows
ligand dissociation fromAR (14). High affinity coactivator LXXLLmotif
binding to estrogen receptor- AF2 or in a TIF2-glucocorticoid recep-
tor chimera also slows ligand dissociation (18, 39). This suggests a recip-
rocal relationship in which ligand binding stabilizes AF2 for motif bind-
ing, and high affinitymotif binding slows ligand dissociation. The lack of
large, defining motif-specific structural differences in the intervening
region between AF2 and ligand binding pocket supports the hypothesis
that high affinity motif binding imparts subtle stabilizing changes that
favor ligand retention, the N/C interaction, coactivator binding, and
ultimately receptor activity in vivo. Some of the subtle dynamic changes
may not be resolved in crystal structures due to rapid kinetics or to the
limitations of resolution, precision accuracy in the structure data, and
superpositions.
Slow androgen dissociation caused by AR V715M and H874Y in
prostate cancer is associated with increased binding of the LXXLL and
FXXLF motifs. T877A, on the other hand, slows androgen dissociation
without increasing motif binding. This apparent disconnect for T877A
indicates that androgen dissociation slower than that of wild-type AR is
not sufficient to increase LXXLL motif binding. The structural changes
from T877A appear to be limited to the local environment of the ligand
binding pocket and are not transmitted to neighboring regions. Simi-
larly, the previously described effects of V730M positioned in AF2 were
limited predominantly to the AF2 surface because coactivator LXXLL
motif binding increased but V730M did not alter androgen dissociation
(13). On the other hand, V715M and H874Y are positioned between
AF2 and the ligand binding pocket and have bidirectional stabilizing
effects on ligand and motif binding. Each of these four mutations
increases AR activation in response to the weaker adrenal androgens.
Ligand binding domain mutations in prostate cancer can therefore
increase AR transcriptional activity through subtle structural changes
that favor ligand binding and/or coactivator recruitment.
Structures of the AR ligand binding domain bound to R1881 and
FXXLF or LXXLL motif peptides suggest an induced fit mechanism
whereby changes are limited predominantly to side chains in the coac-
tivator binding surface (13). Equilibrium androgen binding affinity was
maintained by the AIS and prostate cancer mutants in this study, indi-
cating absence of major structural changes in the interior of the ligand
binding domain. We nevertheless observed effects on ligand retention,
coactivator recruitment, and receptor activity. A recent computer sim-
ulation of the glucocorticoid receptor (GR) investigated the effects of
V571M, a residue in GR positioned three residues NH2-terminal rela-
tive to V715M in AR. GR V571M increased transcriptional activity and
binding specificity for aldosterone (40). Like V715M and H874Y in AR,
V571M is positioned between the coactivator and ligand binding sur-
faces in GR. The in silico molecular dynamic studies of GR V571M
predicted changes of less than 0.03 nm, supporting increased coactiva-
tor recruitment through subtle structural remodeling in AF2.
A model (Fig. 14) is suggested whereby different functional states of
the receptor arise fromglobal changes in structural stability of the ligand
binding domain. Ligand binding increases AR stability that is necessary
for motif binding to AF2. Receptor activity is augmented by AR muta-
tions such as V715M and H874Y in AF2 and ligand binding boundary
region that favor a more stable structural state and slower ligand disso-
FIGURE 14. Two-state model of steroid receptor ligand binding and coactivator
recruitment. High affinity agonist binding induces subtle conformational changes in
the ligand binding domain that allow for FXXLF or LXXLL motif binding to AF2. A full
agonist effect requires slow ligand dissociation, which is achieved as a result of inherent
properties of the ligand (e.g. DHT for AR) and is increased by high affinity motif binding to
AF2. In the two-state model, high affinity slow dissociating ligands stabilize the active
closed state. Faster dissociating ligands that are weaker agonists or antagonists favor the
open state. Steroid receptor activity depends on an equilibrium between open and
closed states. Naturally occurring AR AF2 mutations impact AR activity in vivo by shifting
the equilibrium between open and closed states without altering equilibrium agonist
binding affinity. AF2 mutations that decrease AR transcriptional activity and cause the
androgen insensitivity syndrome (AIS) favor the open state, causing more rapid andro-
gen dissociation through effects at the AF2 surface, at the boundary between AF2 and
the ligand binding pocket, or more directly at the ligand gateway at the base of AF2 helix
12. In contrast, prostate cancer mutations can increase AR transcriptional activity by
favoring the closed state, slowing ligand dissociation and improving FXXLF (FX) and
LXXLL (LX) motif binding. The effect of AIS and prostate cancer mutations demonstrate
ligand-dependent structural communication between AF2 and the ligand binding
pocket mediated by subtle changes that the inherent stability of the ligand binding
domain. The model suggests steroid receptor activity in vivo increases by prolonged
retention time of bound ligand.
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ciation and improved AR FXXLF or coactivator LXXLL motif binding.
The active state is achieved by agonist binding and favored bymutations
that lend stability through mechanisms such as reduced backbone fluc-
tuations and improved anchoring of helices 3 and 12 as suggested forGR
V571M (40). If similar to GR V571M, methionine in the AR prostate
cancermutantV715Mmight be better accommodated and improve van
der Waals interactions that increase overall stability of the ligand bind-
ing domain. Increased inherent stability of the ligand binding domain by
prostate cancer mutations enhance the AR response to weaker or lower
concentrations of androgens. Mutations that decrease structural stabil-
ity of the ligand binding domain reduce receptor activity in response to
circulating androgens and cause AIS. Single amino acid substitutions
alter the equilibrium between the active closed state and inactive open
state that impacts ligand and coactivator binding and ultimately recep-
tor activity.
Increased Coactivator Recruitment in Prostate Cancer—Anumber of
mechanisms have been proposed to account for AR-mediated increases
in cell growth in prostate cancer. These include AR gene amplification
(41), increased cross-talk through growth factor signaling pathways
(32), increased SRC/p160 coactivator expression (42), and AR muta-
tions. The reported ARmutation rate in prostate cancer varies (43–47)
with recent studies suggesting a frequency of 5% (43, 48–52) that
increases in later stages of the disease following androgenwithdrawal or
anti-androgen therapy (48, 53–55). The low incidence of ARmutations
in early stage clinical specimens argues against their role in prostate
cancer initiation (54). On the other hand, functional mutations that
arise during tumor progression associated with genetic instability sug-
gest positive selection for tumor cell survival (21, 56). Most ARmutants
in prostate cancer retain AR transcriptional activity in response to tes-
tosterone or DHT, and nearly half the reported mutants are active in
response to a range of ligands, including adrenal steroids (21, 25, 28, 52,
57, 58). AR mutations described here can contribute to increased AR
functional activity and favor prostate cancer cell survival and expansion
through mechanisms that include increased retention time of bound
androgen or other steroids, increased SRC/p160 coactivator recruit-
ment, and increased AR stability.
The prostate cancer mutations studied in this report were identified
previously in prostate cancer specimens and cell lines (21, 22, 25, 27, 28,
44, 52, 59). T877A occurs in the LNCaP cell line (22, 27) and inmultiple
specimens of prostate cancer (52). Thr-877 is in the linker region before
AF2 helix 12 and in the ligand pocket close to ringsC andDof the bound
steroid. The T877A mutation increases the space around the steroid
D-ring to accommodate other steroids, consistent with the promiscu-
ous ligand binding properties of this mutant (34, 57, 59–62). His-874 in
helix 10 is between AF2 and the ligand binding pocket (61, 63) above
rings C andD of the bound steroid. H874Ywas identified in the CWR22
human prostate cancer xenograft and also displays reduced ligand spec-
ificity (21). V715M is in helix 3 at the boundary between AF2 and the
steroid A-ring side of the binding pocket and was identified in a poorly
differentiated recurrent late stage prostate cancer (25).
The similar effects of H874Y and V715M on androgen dissociation
and FXXLF and LXXLL motif binding may result from different struc-
tural influences. H874Y would displace a conserved structural water
shown in Fig. 12, which might allow direct hydrogen bonding to the
helix 5 backbone. V715M may increase hydrophobic interactions to
stabilize ligand binding. It is noteworthy that 6 other methionine resi-
dues reside directly in the ligand binding pocket and that His-874 and
Val-715 are on opposite sides of AF2, each within 5 Å of Trp-741, a
hydrophobic residue that contacts the ligand and has a role in retaining
ligand (10). H874Y and V715M introduce extended hydrophobic side
chains that improve interactions with Trp-741 that may prolong ligand
retention time by stabilizing Trp-741 and optimizing contacts between
Trp-741 and the ligand. T877A also lies 5 Å from Trp-741. The sur-
prisingly well compensated alanine substitution of T877A forfeits a
hydrogen bond to theD-ring of testosterone andDHT (34, 64), support-
ing the importance of hydrophobic interactions in stabilizing bound
ligand. Interactions between Trp-741 and bound ligandmay have a role
in establishing the DHT and testosterone dissociation rates from wild-
type AR.
Prostate cancers are initially androgen-dependent, regress after
androgen deprivation therapy, and resume growth after a period of
remission despite low circulating androgen (48, 49, 65). AR is expressed
in most recurrent prostate cancers (66) and likely contributes to recur-
rent tumor growth (67, 68). Recent studies have shown DHT levels
decline in recurrent prostate cancer tissue following androgen depriva-
tion therapy, whereas testosterone persists at tissue levels similar to
benign prostatic hyperplasia (69). AR mutations that slow dissociation
of testosterone or weaker adrenal androgens may stabilize the ligand
binding domain and facilitate growth of recurrent prostate cancer
through AR mechanisms in concert with enhanced mitogen signaling.
Why DHT Is a More Potent Androgen than Testosterone—Our char-
acterization of AIS and prostate cancer AR mutants indicates a func-
tional link between androgen dissociation rate and AR activity that par-
allels the known physiological potencies of testosterone and DHT. AR
binds these two biologically active androgens with similar equilibrium
binding affinity (Kd) determined from the ratio of association and dis-
sociation rate constants (31). Yet testosterone dissociates 3 times
faster than DHT. Dissociation of both androgens is slowed by the AR
N/C interaction mediated by FXXLF motif binding to AF2, which
decreasesARdegradation and increases androgen-dependent gene acti-
vation (11, 16). The importance of prolonged ligand retention for ste-
roid receptor activity is also applicable to estrogen receptor-, which
binds estriol and 17-estradiol with similar high affinity, but like the
relationship between testosterone and DHT, estriol dissociates more
rapidly and is a weaker estrogen than 17-estradiol (70). More recent
evidence indicates that removal of the ligand-bound estrogen recep-
tor- from chromatin through degradation in a transcription-coupled
manner is another important mechanism of transcriptional control
(71, 72).
A full or amplified agonist response mediated by AR and perhaps
other steroid receptors appears to depend on sufficient ligand retention
time to maintain structural stability in the ligand binding domain. The
human 5-reductase deficiency syndrome indicates that DHT is
required for AR functional activity during embryonic development.
Naturally occurring mutations in the human 5-reductase type 2 gene
reduce the conversion of testosterone to DHT, cause ambiguous exter-
nal sex phenotypes, and reduce prostate size in 46,XY genetic males
(73). AR mutations in prostate cancer can slow the dissociation of tes-
tosterone to a rate similar to that of DHT, which increases AR stability
and transcriptional activity in response to testosterone or other weaker
androgens in this disease. Ligand retention time as a key determinant of
AR functional activity is supported by the rapid dissociation rates of
high affinity AR antagonists (35).
Requirements for AR Stabilization—Most steroid receptors are
degraded subsequent to agonist-induced gene activation, presumably as
a feedback mechanism to limit the hormone response. AR appears an
exception because it is degraded more slowly in the presence of bound
androgen (74), and stabilization is linked to increased transcriptional
activity in vivo. AR degradation increases in response to mutations that
increase androgen dissociation and cause AIS (20). Conversely, AR
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mutations in prostate cancer can further slow androgen dissociation,
stabilize AR, and contribute to increased androgen-dependent and -in-
dependent AR activity in prostate cancer. The cancer-testis protein
MAGE-11 selectively binds the AR NH2-terminal FXXLF motif and
competes for the ARN/C interaction. Binding ofMAGE-11 relieves the
competitive inhibition of SRC/p160 coactivator LXXLL motif binding
to AF2 caused by AR FXXLF motif binding in the N/C interaction,
thereby increasing androgen dissociation and AR turnover. As a result,
AR functional activity increases by way of greater SRC/p160 coactivator
recruitment (36).
A number of mechanisms involving increased SRC/p160 coactivator
recruitment appear to contribute to greater AR activity in clinically
recurrent prostate cancer. These include increased expression levels of
TIF2 and SRC1 (42) and a broader spectrum of active androgens result-
ing from mutations like T877A (21, 27) and H874Y (21, 26) and muta-
tions such as V730M that increase coactivator LXXLL motif binding
without altering the androgen dissociation rate (13).Herewe report that
AR mutations can provide inherent structural stability to the ligand
binding domain, slow androgen dissociation, and improve SRC/p160
coactivator recruitment. SRC/p160 coactivator binding increases
receptor-mediated gene activation through the recruitment of CBP/
p300 and PCAF for histone acetylation and chromatin remodeling.
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